[go: up one dir, main page]

DE60210402D1 - System zur Abgabe einer Tobramycin-Formulierung - Google Patents

System zur Abgabe einer Tobramycin-Formulierung

Info

Publication number
DE60210402D1
DE60210402D1 DE60210402T DE60210402T DE60210402D1 DE 60210402 D1 DE60210402 D1 DE 60210402D1 DE 60210402 T DE60210402 T DE 60210402T DE 60210402 T DE60210402 T DE 60210402T DE 60210402 D1 DE60210402 D1 DE 60210402D1
Authority
DE
Germany
Prior art keywords
delivering
less
tobramycin
aminoglycoside antibiotic
tobramycin formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE60210402T
Other languages
English (en)
Other versions
DE60210402T2 (de
Inventor
J Speirs
A Schaeffler
B Challoner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23123791&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60210402(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of DE60210402D1 publication Critical patent/DE60210402D1/de
Application granted granted Critical
Publication of DE60210402T2 publication Critical patent/DE60210402T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DE60210402T 2001-05-18 2002-05-17 System zur Abgabe einer Tobramycin-Formulierung Revoked DE60210402T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29223401P 2001-05-18 2001-05-18
US292234P 2001-05-18
PCT/US2002/015999 WO2002094217A1 (en) 2001-05-18 2002-05-17 Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics

Publications (2)

Publication Number Publication Date
DE60210402D1 true DE60210402D1 (de) 2006-05-18
DE60210402T2 DE60210402T2 (de) 2006-12-07

Family

ID=23123791

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60210402T Revoked DE60210402T2 (de) 2001-05-18 2002-05-17 System zur Abgabe einer Tobramycin-Formulierung

Country Status (11)

Country Link
US (8) US20030143162A1 (de)
EP (2) EP1320355B1 (de)
JP (2) JP2004534763A (de)
AT (1) ATE322249T1 (de)
AU (1) AU2010210026A1 (de)
CA (1) CA2447600C (de)
DE (1) DE60210402T2 (de)
DK (1) DK1320355T3 (de)
ES (1) ES2261735T3 (de)
PT (1) PT1320355E (de)
WO (1) WO2002094217A1 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW465235B (en) 1998-09-17 2001-11-21 United Video Properties Inc Electronic program guide with digital storage
EP1320355B1 (de) 2001-05-18 2006-04-05 Chiron Corporation System zur Abgabe einer Tobramycin-Formulierung
US20040022740A1 (en) * 2001-07-10 2004-02-05 Baker William R. Macrolide formulations for inhalation and methods of treatment of endobronchial infections
CA2456746A1 (en) * 2001-08-20 2003-02-27 Transave, Inc. Method for treating lung cancers
ES2364636T3 (es) 2001-12-19 2011-09-08 Novartis Ag Administración pulmonar de aminoglucósidos.
US7607436B2 (en) * 2002-05-06 2009-10-27 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
US8245708B2 (en) * 2002-05-07 2012-08-21 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
US9186322B2 (en) * 2002-08-02 2015-11-17 Insmed Incorporated Platinum aggregates and process for producing the same
EP1545459A4 (de) * 2002-08-02 2007-08-22 Transave Inc Platinaggregate und verfahren zu ihrer herstellung
AU2002953095A0 (en) * 2002-11-29 2002-12-19 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
ES2552682T3 (es) 2003-03-10 2015-12-01 Merck Sharp & Dohme Corp. Agentes antibacterianos novedosos
US20070071686A1 (en) * 2003-10-15 2007-03-29 Pari Gmbh Liquid preparation containing tobramycin
US20050249822A1 (en) * 2004-03-18 2005-11-10 Transave, Inc. Administration of cisplatin by inhalation
US20070065522A1 (en) * 2004-03-18 2007-03-22 Transave, Inc. Administration of high potency platinum compound formulations by inhalation
US7943118B2 (en) 2004-05-17 2011-05-17 Gilead Sciences, Inc. Aerosolized fosfomycin/aminoglycoside combination for the treatment of bacterial respiratory infections
WO2005112957A1 (en) * 2004-05-21 2005-12-01 Transave, Inc. Treatment of lung diseases and pre-lung disease conditions
US20080214481A1 (en) 2004-06-18 2008-09-04 Novartis Vaccines And Diagnostics, Inc. Methods of Treatment of Endobronchial Infections
KR20070089693A (ko) * 2004-11-08 2007-08-31 트랜세이브, 인코포레이티드 지질-기재 플래티넘 화합물 제형을 복막내 투여하여 암을치료하는 방법
AU2013206401B2 (en) * 2005-09-29 2016-06-23 Novartis Ag Antibiotic formulations, unit doses, kits, and methods
CA2622193A1 (en) * 2005-09-29 2007-04-12 Nektar Therapeutics Antibiotic formulations, unit doses, kits, and methods
US20070190180A1 (en) * 2005-11-08 2007-08-16 Pilkiewicz Frank G Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
WO2007056264A2 (en) * 2005-11-08 2007-05-18 Transave, Inc. Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
US20070190181A1 (en) * 2005-11-08 2007-08-16 Pilkiewicz Frank G Methods of treating cancer with lipid-based platinum compound forumulations administered intravenously
US20070122350A1 (en) * 2005-11-30 2007-05-31 Transave, Inc. Safe and effective methods of administering therapeutic agents
HUE029994T2 (en) 2005-12-08 2017-04-28 Insmed Inc Lipid-based preparations of antinfectants for the treatment of lung infections
US8337814B2 (en) * 2005-12-15 2012-12-25 Topical Sinus Therapeutics, Inc. Treatment of active infections, sinusitis, rhinitis, and related neurological disorders and related compositions
JP2008199905A (ja) * 2007-02-16 2008-09-04 Snow Brand Milk Prod Co Ltd 乳酸菌生残性向上剤
EP2214484A4 (de) 2007-10-25 2013-01-02 Cempra Pharmaceuticals Inc Verfahren zur herstellung von antibakteriellen makrolid-wirkstoffen
CN101981688B (zh) * 2008-04-02 2014-04-02 Imec公司 制造半导体器件的方法以及半导体器件
EP2358379B1 (de) * 2008-10-24 2015-12-16 Cempra Pharmaceuticals, Inc. Bioabwehr mt triazolhaltigen makroliden
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
US9480679B2 (en) 2009-09-10 2016-11-01 Cempra Pharmaceuticals, Inc. Methods for treating malaria, tuberculosis and MAC diseases
MX361413B (es) 2010-03-22 2018-12-05 Cempra Pharmaceuticals Inc Star Formas cristalinas de un macrólido y usos para las mismas.
AU2011255464C1 (en) 2010-05-20 2017-02-23 Cempra Pharmaceuticals, Inc. Processes for preparing macrolides and ketolides and intermediates therefor
EP2593110B1 (de) 2010-07-12 2021-01-06 Xellia Pharmaceuticals ApS Behandlung von lungeninfektionen mittels verabreichung von tobramycin in form von aerolisierung
KR20180110181A (ko) 2010-09-10 2018-10-08 셈프라 파마슈티컬스, 인크. 질환을 치료하기 위한 수소결합 형성 플루오로 케토라이드
CN103702663A (zh) 2011-07-12 2014-04-02 卡迪斯制药公司 治疗呼吸机相关肺炎(vap)和呼吸机相关气管(vat)支气管炎的阿米卡星和磷霉素组合的制剂以及方法和系统
US8826904B2 (en) 2011-07-12 2014-09-09 Cardeas Pharma Corporation Formulations of aminoglycoside and fosfomycin combinations and methods and systems for treatment of ventilator associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis
EP2830632A4 (de) 2012-03-27 2015-10-21 Cempra Pharmaceuticals Inc Parenterale formulierungen zur verabreichung von makrolid-antibiotika
GB201208080D0 (en) 2012-05-09 2012-06-20 Norton Healthcare Ltd Tobramycin formulation
EP2892524B1 (de) 2012-09-04 2020-11-25 Eleison Pharmaceuticals, LLC Prävention eines lungenkarzinomrezidivs mit lipidkomplexiertem cisplatin
JP6529438B2 (ja) 2012-11-29 2019-06-12 インスメッド インコーポレイテッド 安定化されたバンコマイシン処方物
WO2014108469A1 (en) 2013-01-11 2014-07-17 Xellia Pharmaceuticals Aps Polymyxins, compositions, methods of making and methods of use
JP6426696B2 (ja) 2013-03-14 2018-11-21 センプラ ファーマシューティカルズ，インコーポレイテッド 呼吸器疾患の治療のための方法および製剤
BR112015023670A2 (pt) 2013-03-15 2017-07-18 Cempra Pharmaceuticals Inc processo para preparar um composto
EP3466432B1 (de) 2014-05-15 2020-07-08 Insmed Incorporated Verfahren zur behandlung von pulmonaler mykobakterieller nichttuberkuloseinfektionen
EP3166960B1 (de) 2014-07-09 2019-08-07 Xellia Pharmaceuticals ApS Niedrigsubstituierte polymyxine und zusammensetzungen davon
CN106794221B (zh) 2014-10-03 2021-12-10 埃克斯利亚制药有限公司 组合物
PL3200762T3 (pl) 2014-10-03 2019-08-30 Xellia Pharmaceuticals Aps Urządzenie do inhalacji
US10617703B2 (en) 2014-12-10 2020-04-14 Cmpd Licensing, Llc Compositions and methods for treating an infection
US10898455B2 (en) 2016-01-07 2021-01-26 Cmpd Licensing, Llc Urea cream formulations
US11278590B2 (en) 2015-08-05 2022-03-22 Cmpd Licensing, Llc Compositions and methods for treating nail infections
US11793783B2 (en) 2015-08-05 2023-10-24 Cmpd Licensing, Llc Compositions and methods for treating an infection
US11690815B2 (en) 2015-08-05 2023-07-04 Cmpd Licensing Llc Hyperkeratotic skin condition treatments and compositions
US11684567B2 (en) 2015-08-05 2023-06-27 Cmpd Licensing, Llc Compositions and methods for treating an infection
US10898491B2 (en) 2015-12-18 2021-01-26 Cmpd Licensing, Llc Compositions and methods for treating an infection
US11446236B2 (en) 2015-08-05 2022-09-20 Cmpd Licensing, Llc Topical antimicrobial compositions and methods of formulating the same
US9999604B2 (en) 2016-11-17 2018-06-19 Cmpd Licensing, Llc Compounded solutions of diclofenac and lidocaine and methods
US10525025B2 (en) 2016-11-17 2020-01-07 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
EP3773505A4 (de) 2018-03-30 2021-12-22 Insmed Incorporated Verfahren zur kontinuierlichen herstellung von liposomalen arzneimittelprodukten
WO2020163416A1 (en) * 2019-02-05 2020-08-13 Mylan Inc Devices and methods for tobramycin inhalation treatment

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993223A (en) 1974-07-25 1976-11-23 American Home Products Corporation Dispensing container
US4502616A (en) 1982-01-04 1985-03-05 Health Care Concepts, Inc. Single use vial
GB8801655D0 (en) 1988-01-26 1988-02-24 Waverley Pharma Ltd Ampoules
DE68904082T2 (de) 1988-01-28 1993-07-29 Lameplast Srl Flaeschchenkette fuer pharmazeutische, kosmetische und andere produkte.
GB8802349D0 (en) 1988-02-03 1988-03-02 Waverley Pharma Ltd Ampoule with luer
DE3916840A1 (de) 1988-09-21 1990-03-29 Bernd Hansen Ampulle
US5409125A (en) 1989-12-11 1995-04-25 Aktiebolaget Astra Unit dose container
CA2027690A1 (en) 1990-10-18 1992-04-19 Christian Laing Plastic ampul
FR2687066A1 (fr) 1992-02-06 1993-08-13 Oreal Ampoule autocassable.
US5508269A (en) * 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
US5758637A (en) * 1995-08-31 1998-06-02 Aerogen, Inc. Liquid dispensing apparatus and methods
US6083922A (en) 1996-04-02 2000-07-04 Pathogenesis, Corp. Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis
PL348812A1 (en) * 1998-12-17 2002-06-17 Pathogenesis Corp Method for the treatment of severe chronic bronchitis (bronchiectasis) with an aerosolized antibiotic
SE9902627D0 (sv) * 1999-07-08 1999-07-08 Siemens Elema Ab Medical nebulizer
DE19953317C1 (de) 1999-11-05 2001-02-01 Pari Gmbh Inhalationsvernebler
EP1320355B1 (de) 2001-05-18 2006-04-05 Chiron Corporation System zur Abgabe einer Tobramycin-Formulierung

Also Published As

Publication number Publication date
US20030143162A1 (en) 2003-07-31
US20040265241A1 (en) 2004-12-30
US7825095B2 (en) 2010-11-02
EP2186508A3 (de) 2010-08-25
US20120101055A1 (en) 2012-04-26
US20050201947A1 (en) 2005-09-15
ES2261735T3 (es) 2006-11-16
PT1320355E (pt) 2006-08-31
US20050207987A1 (en) 2005-09-22
ATE322249T1 (de) 2006-04-15
CA2447600C (en) 2015-10-20
WO2002094217A1 (en) 2002-11-28
US20080095717A1 (en) 2008-04-24
JP2004534763A (ja) 2004-11-18
CA2447600A1 (en) 2002-11-28
EP1320355B1 (de) 2006-04-05
AU2010210026A1 (en) 2010-09-02
DK1320355T3 (da) 2006-07-31
DE60210402T2 (de) 2006-12-07
EP2186508A2 (de) 2010-05-19
JP2009269923A (ja) 2009-11-19
US20110005518A1 (en) 2011-01-13
EP1320355A1 (de) 2003-06-25
US6890907B2 (en) 2005-05-10
US20040131555A1 (en) 2004-07-08
US8507454B2 (en) 2013-08-13

Similar Documents

Publication Publication Date Title
DE60210402D1 (de) System zur Abgabe einer Tobramycin-Formulierung
BR0108730A (pt) Sistema, dispositivo e método para administração de uma droga, bocal de um dispositivo de administração de droga, dispositivo para administração de doses unitárias múltiplas de uma droga, métodos para preparação de um sistema de administração de droga e de uma formulação de droga e para tratamento de um paciente que necessita de doses múltiplas de uma droga, formulação de droga e multiparticulados
KR100910888B1 (ko) 에어로졸화 이송을 위한 적절한 토브라마이싱의 조성물
CA2166312C (en) Compositions for nasal administration of desmopressin
WO2002043750A3 (en) Method for the stabilizing of biomolecules (e.g. insulin) in liquid formulations
IL139229A0 (en) Drug delivery system comprising a tightly compacted solid medicament stock
BR0109875A (pt) Tratamento de doenças respiratórias
EP0861667A3 (de) Partikelförmige Mittel
NZ552047A (en) Method of treatment of endobronchial infections
BR9915095A (pt) Composição farmacêutica ministrável em aerosol
AU1079701A (en) Oral transmucosal drug dosage using solid solution
MY144021A (en) Pharmaceutical delivery system
EP0693924A4 (de) Verfahren für die in-vivo-verabreichung von biologischen substanzen und hierfür verwendbare zusammensetzungen
JP2004534763A5 (de)
PT1317419E (pt) Compostos e composições de ácido cianofenoxicarboxílico para administrar agentes activos
MXPA03000353A (es) Medicamentos para tratamiento quimioterapeutico de enfermedades.
IL101056A (en) Composition for nasal treatment
WO2002003998A3 (en) Macrolide formulations for inhalation and methods of treatment of endobronchial infections
MXPA05009629A (es) Composiciones que contienen trospio.
BR9812553A (pt) Formulação medicamentosa com liberação de substância ativa controlada
ATE388687T1 (de) Medikamentöse verabreichung von nikotin in form von kaugummi
CA2564546A1 (en) Aerosolized fosfomycin/aminoglycoside combination for the treatment of bacterial respiratory infections
WO2005044186A3 (en) Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same
WO2005037256A3 (de) Flüssige zubereitung enthaltend tobramycin
NO20041011L (no) Inhaleringssammensetninger omfattende tricykliske 5,6-dihydro-9H-pyrazolo(3,4-C) -1,2,4-triazolo(4,3-alfa)pyridiner

Legal Events

Date Code Title Description
8363 Opposition against the patent
8327 Change in the person/name/address of the patent owner

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS,INC.(N.D.GES, US

8331 Complete revocation